Keywords: Admelog; Afrezza; Apidra; Basaglar; Basal insulins; Fiasp; Humalog; Humulin; Lantus; Levemir; Long-acting insulin/GLP-1 receptor agonist combinations; Novolin; Novolog; Novorapid; Prandial insulin; ReliOn; Soliqua; Toujeo; Tresiba; Xultophy; adverse effects; degludec; detemir; dosage; efficacy; glargine; insulin; liraglutide; lixisenatide; pregnancy; safety; type 2 diabetes.